LLY Stock: Unusual Options Activity Flags Bearish Hedge as Eli Lilly Shares Climb
By TrendSpider Editor
Eli Lilly and Company is drawing attention in the options market today, with three unusual contracts totaling $1,356,768 in premium standing out against a backdrop of rising share prices. LLY shares are trading at $892.34, up 1.67% on the session, while a large put contract suggests at least one tra
LLY Stock: Unusual Options Activity Flags Bearish Hedge as Eli Lilly Shares Climb
Eli Lilly and Company is drawing attention in the options market today, with three unusual contracts totaling $1,356,768 in premium standing out against a backdrop of rising share prices. LLY shares are trading at $892.34, up 1.67% on the session, while a large put contract suggests at least one trader is positioning for potential downside. The stock currently sits closer to the upper half of its 52-week range of $623.79 to $1,133.95, reflecting a meaningful recovery from its annual lows but still well off peak levels.
Key Drivers of the LLY Stock Move
- Main Catalyst: Three unusual options contracts have been flagged on LLY today, headlined by a PUT at the $790 strike expiring May 15, 2026, carrying a block size of 600 contracts and a premium of $1,233,360. This single contract accounts for the overwhelming majority of total unusual premium activity. Two call contracts, one at the $660 strike expiring April 10, 2026, and another at the $890 strike expiring April 2, 2026, round out the unusual flow.
- Bull Case: Both call contracts are in-the-money, with the $660 call sitting deeply ITM and the $890 call just below the current price of $892.34. The $890 call expiring in just three days carries an open interest ratio of 206%, signaling outsized demand relative to existing open interest and near-term conviction among call buyers.
- Bear Case: The dominant transaction by dollar value is a bearish one. The $790 put expiring May 15, 2026, is out-of-the-money but commands $1,233,360 in premium on 600 contracts, representing the bulk of today's unusual activity. With an open interest ratio of only 39%, this contract also reflects a more crowded positioning context, suggesting it may be a targeted hedge against a pullback of roughly 11.5 points from current levels.
The forward setup for LLY is a study in contrasts. The stock has staged a notable rebound off its 52-week low of $623.79, and the in-the-money call activity reflects some near-term bullish positioning. However, the size and premium concentration of the May put suggests institutional players may be using this rally as an opportunity to hedge or speculate on a near-term reversal before the contract expires in roughly six weeks. Investors will be watching closely for any pipeline updates, regulatory news, or macroeconomic shifts that could drive the next directional move in the stock.
LLY Unusual Options Activity
- Contract 1: CALL | Strike: $660 | Expiry: April 10, 2026 | Volume: 3 | Open Interest: 1,000% | Status: ITM | Premium: $70,440
- Contract 2: PUT | Strike: $790 | Expiry: May 15, 2026 | Volume: 600 | Open Interest: 39% | Status: OTM | Premium: $1,233,360
- Contract 3: CALL | Strike: $890 | Expiry: April 2, 2026 | Volume: 33 | Open Interest: 206% | Status: ITM | Premium: $52,968
Total unusual premium across all three contracts comes to $1,356,768. The put contract at $790 dominates the activity, representing approximately 91% of total premium. The two call contracts, both in-the-money and expiring within the next 11 days, reflect shorter-duration bullish bets relative to the longer-dated bearish hedge.
LLY Seasonality
Late March and early April have historically been an active period for pharmaceutical names as investors position ahead of major industry conferences and mid-year pipeline readouts. The clustering of near-term call expirations in the first two weeks of April may reflect traders looking to capitalize on any catalyst-driven momentum heading into the spring.
LLY Relative Performance
LLY is up 1.67% today, trading at $892.34. The stock remains significantly below its 52-week high of $1,133.95, representing a gap of more than $241 from peak levels, but has recovered substantially from the 52-week low of $623.79. The current price places LLY roughly in the middle of its annual range, suggesting the market is still in the process of re-rating the stock after a volatile year for large-cap pharmaceutical equities.